Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.71 USD
Change Today 0.00 / 0.00%
Volume 298.5K
NBY On Other Exchanges
As of 8:04 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

novabay pharmaceuticals inc (NBY) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/18/14 - $1.30
52 Week Low
02/27/15 - $0.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

novabay pharmaceuticals inc (NBY) Related Businessweek News

No Related Businessweek News Found

novabay pharmaceuticals inc (NBY) Details

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It offers Aganocide compounds, including auriclosene irrigation solution to reduce urinary catheter blockage and encrustation; an eye drop formulation of auriclosene for treating adenoviral conjunctivitis; and a gel formulation of auriclosene for treating impetigo, a highly contagious skin infection. The company also provides NeutroPhase, a skin and wound cleanser for non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

29 Employees
Last Reported Date: 03/6/14
Founded in 2000

novabay pharmaceuticals inc (NBY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $440.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $316.7K
Senior Vice President of Business & Corporate...
Total Annual Compensation: $279.1K
Compensation as of Fiscal Year 2013.

novabay pharmaceuticals inc (NBY) Key Developments

NovaBay Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 26, 2015

NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2014 results After-Market on Mar 26, 2015

NovaBay Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 26, 2015

NovaBay Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 26, 2015

NovaBay®Pharmaceuticals, Inc. Signs Avenova and Neutrophase Distribution Agreements

NovaBay®Pharmaceuticals, Inc. announced that it has signed two new distribution agreements to market its products in international markets. Sarmedic Ltd. will have exclusive rights to market and distribute NovaBays innovative eye care product Avenova in Israel. Alpha Pharma LLC will have exclusive rights to market and distribute NovaBays wound cleanser NeutroPhase® in the Ukraine. NovaBay is currently marketing products through distribution agreements with China Pioneer Pharma Holdings in China, Shin-Poong Pharma in South Korea, and Biopharm Group in the Middle East. As a result of these properties and its cleansing function, Avenova is useful in the control of microorganism populations on the eyelids and lashes of patients suffering from such common chronic eye conditions as blepharitis and dry eye syndrome. The same properties have made NeutroPhase a valuable addition to the treatment paradigm used for the deadly flesh-eating disease and for the care of chronic wounds.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBY:US $0.71 USD 0.00

NBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NBY.
View Industry Companies

Industry Analysis


Industry Average

Valuation NBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.6x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVABAY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at